No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
CSTM240726C17000
- 0.76
- 0.000.00%
15min DelayTrading Jul 23 15:22 ET
0.00High0.00Low
0.00Open0.76Pre Close0 Volume0 Open Interest17.00Strike Price0.00Turnover63.34%IV1.14%PremiumJul 26, 2024Expiry Date0.56Intrinsic Value100Multiplier2DDays to Expiry0.20Extrinsic Value100Contract SizeAmericanOptions Type0.7575Delta0.3319Gamma23.11Leverage Ratio-0.0616Theta0.0009Rho17.50Eff Leverage0.0046Vega
Intraday
- 5D
- Daily
News
Deutsche Numis Maintains Constellium(CSTM.US) With Buy Rating, Cuts Target Price to $23
Deutsche Bank Adjusts Constellium SE Price Target to $23 From $24, Maintains Buy Rating
Express News | Corrected-Constellium SE : Deutsche Bank Cuts Target Price to $23 From $24 (Not Raises Target Price to $24 From $23)
BMO Capital Maintains Constellium(CSTM.US) With Buy Rating, Cuts Target Price to $24
Buy Rating Justified: Constellium's Promising Long-Term Outlook Despite Short-Term Challenges
Express News | Constellium SE : BMO Cuts Target Price to $24 From $25
Comments
Despite profit boost from unusual items, Constellium's true earnings power may be less. Future profitability is uncertain, and more factors should be considered. Investors should note 2 warning signs in Constellium's investment analysis.
Constellium's (NYSE:CSTM) Weak Earnings May Only Reveal A Part Of The Whole Picture 1
Constellium's future performance is deemed crucial for shareholders despite expected slowdown in share price growth. However, investors should be aware of the 3 identified warning signs with the company.
Constellium's decent ROE is overshadowed by its high debt level. A high-quality business is one that can achieve high ROE without debt. Between two companies with the same ROE, the less indebted one is generally preferred.
1
Investors could be wary of potential risks including earnings instability, despite the seemingly stable P/E ratio and stronger-than-expected earnings growth. Unidentified risks might also pressure the P/E ratio, holding back share price despite growth predictions.
Gainers:
In reaction to earnings/guidance:
• $Teva Pharmaceutical Industries(TEVA.US$ +24%(also announces agreement for opioids settlement), $Enphase Energy(ENPH.US$ +9.5%, $Spotify Technology(SPOT.US$ +9.2%, $RPC Inc(RES.US$ +8.5%, $Chipotle Mexican Grill(CMG.US$ +8.2%, $Manhattan Associates(MANH.US$ +8.1%, $Hilton Worldwide(HLT.US$ +6.7%, $ChampionX(CHX.US$ +6.1%, $Mr. Cooper Group(COOP.US$ +5.7%, $Constellium(CSTM.US$ +5.5%, $Boston Scientific(BSX.US$ +5.4%, ...
In reaction to earnings/guidance:
• $Teva Pharmaceutical Industries(TEVA.US$ +24%(also announces agreement for opioids settlement), $Enphase Energy(ENPH.US$ +9.5%, $Spotify Technology(SPOT.US$ +9.2%, $RPC Inc(RES.US$ +8.5%, $Chipotle Mexican Grill(CMG.US$ +8.2%, $Manhattan Associates(MANH.US$ +8.1%, $Hilton Worldwide(HLT.US$ +6.7%, $ChampionX(CHX.US$ +6.1%, $Mr. Cooper Group(COOP.US$ +5.7%, $Constellium(CSTM.US$ +5.5%, $Boston Scientific(BSX.US$ +5.4%, ...
10
Read more